Unicycive Therapeutics (UNCY) Accumulated Expenses (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Accumulated Expenses data on file, last reported at $3.1 million in Q1 2026.

• Quarterly Accumulated Expenses fell 26.33% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 26.33% YoY) and the FY2025 annual result came in at $1.5 million, down 20.26% from the prior year.
• Accumulated Expenses climbed to $3.1 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $4.1 million in Q1 2025 to a low of $978000.0 in Q2 2024.
• A 5-year average of $2.2 million and a median of $1.9 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 384.2% — and 2023, when it slumped 55.69%.
• Tracing UNCY's Accumulated Expenses over 5 years: stood at $1.5 million in 2022, then advanced by 28.92% to $1.9 million in 2023, then dropped by 0.37% to $1.9 million in 2024, then retreated by 20.26% to $1.5 million in 2025, then jumped by 100.39% to $3.1 million in 2026.
• The last three Accumulated Expenses figures came in at $3.1 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.